PHP38 HOW EQUITABLE OF HEALTH SERVICE USE AND GOVERNMENT SUBSIDIES IN THAILAND AFTER ACHIEVING UNIVERSAL COVERAGE?  by Prakongsai, P
13th Euro Abstracts A411
to new medicines. Our goal was to determine the time period between the registration 
and reimbursement date in Hungary. METHODS: We selected all newly reimbursed 
pharmacy drugs between January 2004 and April 2010 and looked for the date of 
registration and reimbursement in public websites and Bulletins of EMEA/EMA, 
National Institute of Pharmacy and National Health Insurance Fund. We excluded 
hospital only medicines and drugs with special reimbursement budget from the analy-
sis due to the lack of transparency of reimbursement dates in publicly available data 
sources. RESULTS: 106 newly reimbursed innovative medicines between January 
2004–April 2010 were included into the analysis. The average time period between 
registration and reimbursement was 677 days. CONCLUSIONS: Hungary joined the 
European Union in May 2004 and implemented the EU Transparency Directive. Time 
to reimbursement of innovative medicines in Hungary is signiﬁ cantly longer than the 
recommended 90 + 90 days for pricing and reimbursement process set by Transpar-
ency Directive. The pricing and reimbursement process in Hungary takes more time 
than in 15 European countries included in the EFPIA Patients W.A.I.T. indicator 
database (from 101 to 403 days). Acceleration of patient access to innovative medi-
cines is highly recommended in Hungary.
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OBJECTIVES: In French and English hospitals, there are a lists of drugs ﬁ nanced out 
of scope of casemix-based payment system that are Payment by Result (PbR) and 
“Tariﬁ cation à l’activité” (T2A). We examined a difference in the range of these drugs 
in both countries. METHODS: In the study were included the drugs registered on the 
list “en sus” in French system, the drugs from the high cost drugs list (HCD) and from 
the oncology regimens list in English system. The information is available in ofﬁ cial 
sources. The number and overlap of entities excluded from the casemix-based payment 
system in two countries were determined, as well as similarity rate. RESULTS: 210 
entities are ﬁ nanced out of scope of casemix-based payment system in England and 
101 in France. 69% (145/210) of entities excluded from PbR are not on the list “en 
sus”. Around 36% (36/101) of entities excluded from T2A are not on the English 
lists. There are 65 entities common for both lists; 51% (33/65) are from ATC class L 
(antineoplastic and immunomodulating agents). Four ATC classes have none common 
drugs. The aim of the list in two systems is fair reimbursement of the expensive drugs 
within the casemix-based payment system. In French system this list is used also to 
improve the access to the expensive and innovative drugs. So, 50% (73/145) of the 
entities excluded from PbR and not included on the list “en sus” are on another list 
in French system, the retrocession list. CONCLUSIONS: There is a difference in the 
range of drugs ﬁ nanced out of scope of casemix-based payment system in French and 
English hospitals. More drugs are excluded from the casemix-based payment system 
in England, but it does not facilitate access to new drugs.
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OBJECTIVES: The aim was to examine the current availability and funding of orphan 
drugs in both entities of B&H and compare the obtained data with neighboring 
countries (Croatia, Serbia and Montenegro) and the EU. METHODS: We have ana-
lyzed the current published list of medicines in B&H and neighboring countries. We 
have compared the drugs that have the status of orphans according to the Orphanet 
report. RESULTS: In BiH there are no lists of orphan drugs while some of them are 
included in the list of chemotherapeutic agents and drugs for speciﬁ c diseases (RS). 
Only Croatia has made a special list of expensive medicines containing drugs for 
treatment of hereditary enzyme deﬁ ciency. All countries have imatinib reimbursed. 
Only in the RS and Serbia thalidomide is reimbursed, and Serbia has listed sildenaﬁ l, 
zinc acetate and busulfan. Present practice in all countries is that patients apply 
individualy for orphan drugs reimbursement approval to HIFs. CONCLUSIONS: In 
order to improve access to orphan drugs it is necessary to adopt a national policy 
which will be harmonized with the EU. Decisions on the reimbursement must be based 
on real possibilities and it is necessary to implement appropriate registries for future 
resource allocation decissions.
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OBJECTIVES: To assess the impact of achieving universal coverage (UC) on equity 
in health care ﬁ nance and on ﬁ nancial risk protection from expensive medical care 
costs for Thai households. METHODS: Secondary data analyses using nationally 
representative household surveys conducted by National Statistical Ofﬁ ce, the Socio-
economic Survey 2000 (prior to UC) and 2002–2006 (after UC) to analyze changes 
in progressivity of overall health care ﬁ nance and different health ﬁ nancing sources. 
The share of households facing catastrophic health expenditure in the poorest and 
richest income quintiles prior to and after achieving UC was also assessed. RESULTS: 
The ﬁ nancing of the Thai health care system became more equitable after the UC 
policy was implemented. Improved ﬁ nancial risk protection after achieving UC was 
observed due to the comprehensive beneﬁ t package and literally free at point of ser-
vices. The Kakwani index value for overall health care ﬁ nance changed from −0.0038 
(regressive) in 2000 to positive (progressive) values of 0.0014, 0.0342 and 0.0406 in 
2002, 2004 and 2006, respectively. The share of households facing catastrophic 
spending on health decreased from 5.4% in 2000 to 2.0% in 2006. The 1st (poorest) 
quintile experienced a 77.5% reduction in the proportion of households facing cata-
strophic health expenditure, while there was a 41% reduction in the share of house-
holds in the 5th (richest) quintile. CONCLUSIONS: Factors contributing to equitable 
health ﬁ nance are: the increasing share of progressive ﬁ nancing sources in particular 
direct tax; the decreasing share of the regressive out-of-pocket payments for health. 
Using general taxation to ﬁ nance the poor and the informal sector not only helps reach 
universal coverage, it is also the most progressive ﬁ nancing source. Various factors 
contribute to the low incidence of catastrophic heath expenditure: comprehensive 
beneﬁ t package covering almost all health services which are free at point of use, and 
well-functioning primary care providers.
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OBJECTIVES: To assess trends of equity in health service use and distribution of 
government subsidies to ambulatory services and hospitalization across income gra-
dients of the Thai population prior to and after implementation of the universal cover-
age (UC) policy in 2002 and explained how such equity has been achieved. METHODS: 
Secondary data analyses using nationally representative household surveys conducted 
by National Statistical Ofﬁ ce, the Health and Welfare Survey (HWS) 2001 (prior to 
UC) and 2003–2007 (after UC) to analyze equity in health service use at different 
health care levels and the distribution of government subsidies for health. The analyti-
cal approach employed a standard method for health equity analysis of the large scale 
household surveys proposed by O’Donnell et al. RESULTS: Outpatient and inpatient 
service use of the Thai health systems were both pro-poor before achieving UC in 
2002 due to various government interventions in extending health insurance coverage 
and countrywide distribution of health service infrastructure, and the signiﬁ cant 
increase in human resource production. After the UC policy implementation, the pro-
poor service utilization was further progressed. Overall, public subsidies for health 
were found to be pro-poor for both outpatient and inpatient services with the con-
centration indexes of −0.226, −0.186 and −0.180, in 2003, 2006 and 2007, respec-
tively. District health provider networks, in particular health centres, district and 
provincial hospitals are the major determinants of the pro-poor distribution of service 
utilization and public subsidies, due to their geographical proximity and better access 
by the poor. A comprehensive beneﬁ t package and the provision of services that are 
free at the point of use resulted in the pro-poor beneﬁ t incidence. CONCLUSIONS: 
The pro-poor outcome is the result of an availability of functional primary care at the 
district level, and implementation of the UC policy which focuses on contracting 
primary care networks at the district level.
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OBJECTIVES: The study aimed to compare the retail prices of generics and originator 
brand for ﬁ ve drugs between Jordan and United Kingdom and to investigate the rela-
tion between number of generics available, retail price of originator and generic (s) 
and the effect of time in the market on these prices. METHODS: Prices of originators 
and generics and the number of generics available in each market were obtained from 
the Jordanian Food and Drug Administration, Royal Pharmaceutical Society of Great 
Britain, British National Formulary and Chemist & Druggist generics list. The prices 
were converted to British Pounds expressed per one dose unit. All data was tabulated 
in spreadsheets; prices were compared between the two countries at different preset 
times. RESULTS: The generics of all drugs investigated appeared in the Jordanian 
market before patent expiry of their originator worldwide due to lack of patency regu-
lations in Jordan at the launch time of drugs under investigation (before 2004). Unlike 
the UK, the prices of originator drugs in Jordan did not change when the ﬁ rst generic 
was introduced to the market. The price of generic drugs have dropped dramatically 
in the UK at time of ﬁ rst generic launch approximately by 90% compared to 15% in 
Jordan. There was no apparent correlation between the numbers of generics available 
or the number of years of ﬁ rst generic being in the market and the prices of the drugs 
investigated in both countries. The current prices of all investigated drugs in Jordan 
are higher than the UK particularly for the generics. CONCLUSIONS: Although much 
lower income per capita in Jordan, generic drugs are more expensive than the equiva-
lent prices of same drugs in the UK
